Phase II Study of a Nebulised Nitric Oxide Generating Solution in Patients With Cystic Fibrosis
Status:
Not yet recruiting
Trial end date:
2022-09-26
Target enrollment:
Participant gender:
Summary
- To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to
the end of treatment with RESP301 in patients with cystic fibrosis who have
treatment-naïve or treatment-refractory M. abscessus-pulmonary disease
- To assess the safety and tolerability of RESP301 during treatment (28 days) and follow
up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment
refractory M. abscessus-pulmonary disease